KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Income from Continuing Operations: 2011-2025

Historic Income from Continuing Operations for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -$45.1 million.

  • Supernus Pharmaceuticals' Income from Continuing Operations fell 217.20% to -$45.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.1 million, marking a year-over-year decrease of 131.95%. This contributed to the annual value of $73.9 million for FY2024, which is 5512.84% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Income from Continuing Operations of -$45.1 million as of Q3 2025, which was down 300.53% from $22.5 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Income from Continuing Operations peaked at $38.5 million during Q3 2024, and registered a low of -$45.1 million during Q3 2025.
  • Over the past 3 years, Supernus Pharmaceuticals' median Income from Continuing Operations value was $1.2 million (recorded in 2023), while the average stood at $3.7 million.
  • In the last 5 years, Supernus Pharmaceuticals' Income from Continuing Operations soared by 2,506.53% in 2024 and then plummeted by 9,641.13% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Income from Continuing Operations (Quarterly) stood at $2.4 million in 2021, then skyrocketed by 943.45% to $25.5 million in 2022, then crashed by 95.39% to $1.2 million in 2023, then skyrocketed by 1,208.68% to $15.4 million in 2024, then tumbled by 217.20% to -$45.1 million in 2025.
  • Its last three reported values are -$45.1 million in Q3 2025, $22.5 million for Q2 2025, and -$11.8 million during Q1 2025.